<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Pediatr</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Pediatr</journal-id>
      <journal-title-group>
        <journal-title>BMC Pediatrics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2431</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24410941</article-id>
      <article-id pub-id-type="pmc">3937157</article-id>
      <article-id pub-id-type="publisher-id">1471-2431-14-6</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2431-14-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Acute hepatitis and myositis associated with Erythema infectiosum by Parvovirus B19 in an adolescent</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Koliou</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>mkoliou@spidernet.com.cy</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Karaoli</surname>
            <given-names>Evaggelia</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>dreliak@googlemail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Soteriades</surname>
            <given-names>Elpidoforos S</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>esoteria@hsph.harvard.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Pavlides</surname>
            <given-names>Sylvie</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>yackee@cing.ac.cy</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Bashiardes</surname>
            <given-names>Stavros</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>sbash@cing.ac.cy</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Christodoulou</surname>
            <given-names>Christina</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>cchristo@cing.ac.cy</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Paediatrics, Archbishop Makarios Hospital, 14 Longou Street, 2027, Strovolos Nicosia, Cyprus</aff>
      <aff id="I2"><label>2</label>Cyprus Institute of Biomedical Sciences (CIBS), Nicosia, Cyprus</aff>
      <aff id="I3"><label>3</label>Harvard School of Public Health, Department of Environmental Health, Environmental and Occupational Medicine and Epidemiology (EOME), Boston, MA, USA</aff>
      <aff id="I4"><label>4</label>Department of Virology, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <fpage>6</fpage>
      <lpage>6</lpage>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Koliou et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Koliou et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2431/14/6"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Erythema infectiosum is the most common clinical manifestation of Parvovirus B19 infection although it has also been associated with rheumatologic diseases and various types of systemic vasculitides. Acute hepatitis and benign myositis however are rarely reported in association with Parvovirus B19 infection.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>Here we report a 14-year old male, who developed acute hepatitis and benign myositis associated with erythema infectiosum following Parvovirus B19 infection.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Parvovirus B19 infection has rarely been associated with acute hepatitis and exceptionally rarely with benign myositis. Parvovirus B19 should be considered in the differential diagnosis of acute non-A to E hepatitis and in the case of acute benign myositis presenting with a rash especially in children.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Parvovirus B 19</kwd>
        <kwd>Erythema infectiosum</kwd>
        <kwd>Hepatitis</kwd>
        <kwd>Myositis</kwd>
        <kwd>Cyprus</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Parvovirus is a ubiquitous agent commonly infecting children. By 15 years of age, half of children are seropositive to the virus [<xref ref-type="bibr" rid="B1">1</xref>]. Parvovirus B19 belongs to the erythrovirus genus, which was named after its pronounced tropism for erythrocyte precursor cells. Erythema infectiosum is the most common clinical manifestation of Parvovirus B19 infection transmitted mainly by respiratory droplets, which often occurs in outbreaks among school-aged children. The illness usually starts with fever and non-specific influenza-like symptoms followed by rash, fever and rheumatic symptoms such as arthralgia or arthritis [<xref ref-type="bibr" rid="B2">2</xref>]. In 25% to 50% of cases in immunocompetent patients, infection by Parvovirus B19 is entirely asymptomatic [<xref ref-type="bibr" rid="B3">3</xref>]. There are, however, well characterized clinical syndromes associated with infection. Apart from erythema infectiosum, these include non-immune hydrops fetalis and arthropathy [<xref ref-type="bibr" rid="B1">1</xref>]. Acute hepatitis has rarely been associated with Parvovirus B19 infection [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>] and its association with benign myositis is exceptionally rare with only one case having been reported in the literature [<xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>In the current case report, we present a 14-year old adolescent who developed acute benign hepatitis and concurrent myositis in the context of erythema infectiosum caused by Parvovirus B19.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 14-year old white male, was transferred to our hospital in June 2012 from the Paediatric department of a district hospital because of arthralgias, myalgias and chest pain. The patient was well until 48 hours prior to admission when he started to complain of pain mainly in the upper limbs and chest. The next day he developed fever, rash, malaise and worsening chest pain. A few hours before his visit to the Accident and Emergency department of the district hospital he had a short syncope episode. On the same day he started to feel weakness in both upper and lower limbs, he was unable to walk and was admitted to the district hospital.</p>
      <p>The child&#x2019;s medical history was significant for oral antibiotic therapy for an infected epidydymal cyst. Initially he was prescribed ciprofloxacin for 10 days, then cefuroxime for 7 days and co-trimoxazole for another 7 days. The antibiotic therapy was completed one week before the described health problem. In the two years preceding the episode he had reported two episodes of non-specific allergic rashes.</p>
      <p>The laboratory work-up performed on admission at the tertiary referral hospital revealed elevated creatinine phosphokinase (CPK) 7,643 U/L and CK-MB isoenzyme 75.8 U/L. Troponin levels were&#x2009;&lt;&#x2009;50 mg/dl, alanine aminotransferase 180 U/L, aspartate aminotransferase 253 U/L, &#x3B3;-GT 72 U/L, alkaline phosphatase 146 U/L, total bilirubin 3.14 mg/dl with direct component 1.04 mg/dl. International normalised ratio (INR) was 1.34, and lactate dehydrogenase 760 U/L.</p>
      <p>On the third day of hospitalization the child was transferred to our hospital as a referral and on admission he was relatively well with normal vital signs and temperature 37.6&#xB0;C. On examination, he had an erythematous rash over the face with relative circumoral pallor. An erythematous maculopapular rash was also present over the entire trunk and the extremities. His muscle strength on the upper and lower limbs was decreased (2/5), and the muscles, especially the calves, were slightly painful on palpation, but there was no swelling. The child was unable to walk even after 6 days of hospitalization. In addition, he was complaining of arthralgias especially of the elbow joints but no findings suggestive of arthritis were detected. No abnormal findings were detected from cardiac, respiratory and abdominal examination.</p>
      <p>The rash disappeared on the 7<sup>th</sup> day leaving the lower limbs with a reticulated or lacelike rash more visible during standing and after bathing. His workup included cardiology evaluation with normal ECG, echocardiogram and serial laboratory tests for re-evaluation of his liver function and CPK (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>).</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Laboratory results of the patient during hospitalization and follow up (days counted since admission in the district hospital)</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Laboratory test (normal range)</bold>
              </th>
              <th align="center">
                <bold>Day 4</bold>
              </th>
              <th align="center">
                <bold>Day 5</bold>
              </th>
              <th align="center">
                <bold>Day 6</bold>
              </th>
              <th align="center">
                <bold>Day 7</bold>
              </th>
              <th align="center">
                <bold>Day 11</bold>
              </th>
              <th align="center">
                <bold>One month follow up</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">CPK (26 &#x2013; 171 U/L<hr/></td>
              <td align="center" valign="bottom">7643<hr/></td>
              <td align="center" valign="bottom">5168<hr/></td>
              <td align="center" valign="bottom">2463<hr/></td>
              <td align="center" valign="bottom">325<hr/></td>
              <td align="center" valign="bottom">51<hr/></td>
              <td align="center" valign="bottom">83<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CK-MB (0 &#x2013; 25 U/L)<hr/></td>
              <td align="center" valign="bottom">75.8<hr/></td>
              <td align="center" valign="bottom">44<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">ALT (3 &#x2013; 41 U/L)<hr/></td>
              <td align="center" valign="bottom">180<hr/></td>
              <td align="center" valign="bottom">161<hr/></td>
              <td align="center" valign="bottom">130<hr/></td>
              <td align="center" valign="bottom">92<hr/></td>
              <td align="center" valign="bottom">78<hr/></td>
              <td align="center" valign="bottom">20<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">AST (3 &#x2013; 38 U/L)<hr/></td>
              <td align="center" valign="bottom">253<hr/></td>
              <td align="center" valign="bottom">207<hr/></td>
              <td align="center" valign="bottom">133<hr/></td>
              <td align="center" valign="bottom">59<hr/></td>
              <td align="center" valign="bottom">36<hr/></td>
              <td align="center" valign="bottom">28<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">INR (0.95 &#x2013; 1.02)<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">1.30<hr/></td>
              <td align="center" valign="bottom">1.45<hr/></td>
              <td align="center" valign="bottom">1.37<hr/></td>
              <td align="center" valign="bottom">1.02<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">&#x3B3;-GT (9 &#x2013; 55 U/L)<hr/></td>
              <td align="center" valign="bottom">72<hr/></td>
              <td align="center" valign="bottom">92<hr/></td>
              <td align="center" valign="bottom">95<hr/></td>
              <td align="center" valign="bottom">101<hr/></td>
              <td align="center" valign="bottom">78<hr/></td>
              <td align="center" valign="bottom">17<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">T. Bilirubin (0.3 &#x2013; 1.2 mg/dl)<hr/></td>
              <td align="center" valign="bottom">3.14<hr/></td>
              <td align="center" valign="bottom">3.04<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">1.12<hr/></td>
              <td align="center" valign="bottom">1.02<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Direct Bilirubin (0.1 &#x2013; 0.2 mg/dl)<hr/></td>
              <td align="center" valign="bottom">1.04<hr/></td>
              <td align="center" valign="bottom">1.60<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">0.30<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">LDH (208 &#x2013; 480 U/L)<hr/></td>
              <td align="center" valign="bottom">760<hr/></td>
              <td align="center" valign="bottom">700<hr/></td>
              <td align="center" valign="bottom">457<hr/></td>
              <td align="center" valign="bottom">538<hr/></td>
              <td align="center" valign="bottom">433<hr/></td>
              <td align="center" valign="bottom">428<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Hb (g/dl)<hr/></td>
              <td align="center" valign="bottom">14.7<hr/></td>
              <td align="center" valign="bottom">13.4<hr/></td>
              <td align="center" valign="bottom">12.9<hr/></td>
              <td align="center" valign="bottom">12.7<hr/></td>
              <td align="center" valign="bottom">13.5<hr/></td>
              <td align="center" valign="bottom">15.3<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CRP (neg&#x2009;&lt;&#x2009;0.5 mg/dl)<hr/></td>
              <td align="center" valign="bottom">9.3<hr/></td>
              <td align="center" valign="bottom">12.0<hr/></td>
              <td align="center" valign="bottom">11.0<hr/></td>
              <td align="center" valign="bottom">9.6<hr/></td>
              <td align="center" valign="bottom">2.0<hr/></td>
              <td align="center" valign="bottom">0.1<hr/></td>
            </tr>
            <tr>
              <td align="left">ESR (mm)</td>
              <td align="center">-</td>
              <td align="center">14</td>
              <td align="center">16</td>
              <td align="center">21</td>
              <td align="center">34</td>
              <td align="center">9</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>In summary, the liver enzymes and CPK normalized by day 11. Additional laboratory tests included anti-streptolysin titer 237 IU/ml (normal 0 - 350 IU/ml), negative anti-nuclear antibodies (ANA), negative Mycoplasma IgM, and negative viral studies for IgM antibodies for EBV, CMV, Adenovirus, Measles, and Rubella. Antibodies for hepatitis A, C and Hepatitis B surface antigen were also negative. Serum, lymphocytes and stools were negative for enterovirus RNA and adenovirus DNA as detected by TaqMan based RealTime PCR methods (qualitative assays). Parvovirus B19 DNA as detected by TaqMan based RealTime PCR method [<xref ref-type="bibr" rid="B9">9</xref>] was positive in the serum and lymphocytes. No quantitative PCR was done. IgG for Parvovirus B19 were strongly positive, whereas IgM negative.</p>
      <p>During hospitalization the patient was treated with penicillin 100,000 IU/kg/24h IV for two days and then switched to cefotaxime 100 mg/kg/24h and azithromycin 500 mg/day to complete a 3-day regimen because of high-grade fever, cough and malaise. Blood culture was negative. On day 8 he became afebrile, while his muscle strength returned to normal levels at day 9, when he was able to walk without pain and at day 11 he was discharged home afebrile and in good condition.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>Erythema infectiosum is the most common clinical manifestation of Parvovirus B19 infection transmitted mainly by respiratory droplets. The illness usually runs in a biphasic course, which starts with fever and non-specific flu-like symptoms [<xref ref-type="bibr" rid="B2">2</xref>] followed by rash, fever and rheumatologic manifestations such as arthralgia or arthritis. The second phase develops concurrently with the production of detectable anti-viral antibodies, therefore it is believed that these symptoms are at least partially due to the formation and deposition of immune complexes in the tissues [<xref ref-type="bibr" rid="B1">1</xref>]. A temporary suppression of erythropoiesis usually occurs during the first phase of Parvovirus infection, which is however recognizable only in patients with chronic haemolytic disorders [<xref ref-type="bibr" rid="B3">3</xref>].</p>
      <p>Acute hepatitis has rarely been associated with Parvovirus B19 infection [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. In most of these cases the outcome was favourable, although, in one case, hepatitis lasted for up to 9 months [<xref ref-type="bibr" rid="B7">7</xref>]. Some studies have implicated Parvovirus B19 in cases of liver failure as a result of fulminant hepatitis; however, other studies did not support this association [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. In our case, hepatitis was rather mild. There was an increase in the transaminase levels and the bilirubin and there was evidence of mild hepatic dysfunction as evidenced by an increase of INR; however, the liver abnormalities self-resolved in a few weeks.</p>
      <p>The mechanism by which Parvovirus B19 causes hepatic injury has not been elucidated. Two mechanisms have been proposed: One refers to a direct invasion by the virus that can cause hepatic cell damage [<xref ref-type="bibr" rid="B13">13</xref>], while the other involves an indirect action mainly triggered by an immune response against the virus [<xref ref-type="bibr" rid="B14">14</xref>]. On the cellular level, globoside, a neutral glycolipid, acts as the main cell receptor for the virus and can be found abundantly on the cell membranes of the erythrocyte and its precursors. This provides a possible explanation for most of the underlying pathology linked to the manifestations of Parvovirus B19 infection including transient aplastic crisis and hydrops fetalis [<xref ref-type="bibr" rid="B15">15</xref>]. Globoside has also been detected on the membranes of many other cell types in the human body including the hepatocytes [<xref ref-type="bibr" rid="B16">16</xref>]. It seems that all non-erythroid cells are not permissive to the virus, meaning that despite the virus gains entry into the cells, it cannot replicate [<xref ref-type="bibr" rid="B3">3</xref>]. However, it has been suggested that despite the virus inability to replicate within a non permissive cell, it retains its ability to produce the non structural protein NS1, which can induce apoptosis of the corresponding infected cell [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. This has also been proposed in the case of the hepatocyte and supports the hypothesis of the direct cytopathic effect of Parvovirus B19 on liver cells [<xref ref-type="bibr" rid="B13">13</xref>].</p>
      <p>Co-trimoxazole, administered a week prior to illness could in rare instances result in a similar clinical picture. Most side effects are thought to be due to sulfonamide component. A hypersensitivity syndrome can be induced consisting of fever, rashes and organ involvement of varying severity. The rash may be of different types including maculopapular or urticarial type but erythema nodosum, exfoliative dermatitis can also occur usually in association with arthralgias [<xref ref-type="bibr" rid="B18">18</xref>]. The liver damage is usually mild, consists of a mild transaminase elevation and resolves within a few weeks. However, in rare cases it may progress to fulminant liver failure [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>].</p>
      <p>In our case, some manifestations such as the liver enzyme increase could partially be attributed to the previous administration of co-trimoxazole. However, the lacy appearance of the rash was very characteristic of parvovirus infection. Furthermore, to our knowledge, myositis was never reported in the literature in association to either trimethoprim or sulfonamides. Eosinophilia, a frequent finding associated with hypersensitivity related manifestations of sulfonamides, was undetected in our case.</p>
      <p>In some cases, Parvovirus B19 has been associated with rheumatologic disease in both children and adults [<xref ref-type="bibr" rid="B22">22</xref>] and with various types of systemic vasculitis, which include cases of dermatomyositis [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. In our patient, myositis may be differentiated from previously reported dermatomyositis cases mainly because of its very short and benign course and the fact that auto-antibodies such as ANA were all negative. Up to now, about one year after the episode, the patient remains completely healthy. An electromyogram was not performed on the patient because of the rapid improvement of his condition. The very short course and self-resolution of myositis in our patient supports the hypothesis that the underlying mechanism is much more benign and self-limited. The myositis in our patient could probably fit more into the context of acute benign childhood myositis (BACM) as the one encountered at the early convalescent period of several viral infections including influenza [<xref ref-type="bibr" rid="B24">24</xref>]. BACM is a very benign condition, which follows a few days after a flu-like illness. The CPK is invariably elevated in all such cases. The calf muscles are mainly affected resulting in weakness and inability to walk. In our case the muscle weakness and elevated CPK was detected during the stage of the rash and arthralgia, which may represent the stage of production of antibodies and the formation of immune complexes [<xref ref-type="bibr" rid="B1">1</xref>].</p>
      <p>One of the hypotheses in the pathogenesis of BACM associated with influenza virus infection is the direct invasion of the muscle cells by the virus, which however is not permissive and therefore does not allow the virus to replicate within the muscle cells. Therefore the initial infection of the muscle tissue by the virus results in some muscle fibre necrosis sufficient to cause elevation of the CPK but does not cause a frank inflammation of the muscle tissue [<xref ref-type="bibr" rid="B25">25</xref>]. However, as in the case of hepatitis, there is still uncertainty as to whether the myositis is caused by the direct invasion of the virus or whether an immune mediated mechanism triggered by the virus leads to muscle injury [<xref ref-type="bibr" rid="B26">26</xref>]. Unfortunately, we were unable to clarify this hypothesis since a biopsy was not performed due to the short course of illness.</p>
      <p>To our knowledge, there is only one similar case report of benign myositis during infection by Parvovirus B19 [<xref ref-type="bibr" rid="B8">8</xref>]. That case developed in the context of Erythema infectiosum caused by Parvovirus B19 in a 9-year old child and was also self resolved a few days later. Our case and the one previously reported add to the scientific knowledge associating Parvovirus B19 with a wide range of diseases in both children and adults. Furthermore, it shows that Parvovirus B19 should be considered in the differential diagnosis of acute non-A to E hepatitis and also in the case of acute benign myositis associated with viral infections presenting with a rash.</p>
      <sec>
        <title>Consent</title>
        <p>Written informed consent for publication of this Case report and any accompanying images was obtained from the parent of the patient. A copy of the written consent is available for review by the Editor of this journal.</p>
      </sec>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>ECG: Electrocardiogram; PCR: Polymerase chain reaction; EBV: Epstein-Barr virus; CMV: Cytomegalovirus.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>In detail: MK, ES and SB drafted the manuscript. MK, EK conceived of the idea for the study. MK, EK and ESS participated in its design and coordinated and helped to draft the manuscript. SP, SB and CC carried out the viral molecular analysis. SP carried out the immunoassays. All authors contributed to interpretation of the data and the final version of the manuscript. All authors have read and approved of the final version to be published.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2431/14/6/prepub">http://www.biomedcentral.com/1471-2431/14/6/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Young</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>KE</given-names>
          </name>
          <article-title>Parvovirus B19</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>586</fpage>
          <lpage>597</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra030840</pub-id>
          <pub-id pub-id-type="pmid">14762186</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Anderson</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Higgins</surname>
            <given-names>PG</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Willman</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Kidd</surname>
            <given-names>IM</given-names>
          </name>
          <name>
            <surname>Pattison</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Tyrrell</surname>
            <given-names>DA</given-names>
          </name>
          <article-title>Experimental parvoviral infection in humans</article-title>
          <source>J Infect Dis</source>
          <year>1985</year>
          <volume>152</volume>
          <fpage>257</fpage>
          <lpage>265</lpage>
          <pub-id pub-id-type="doi">10.1093/infdis/152.2.257</pub-id>
          <pub-id pub-id-type="pmid">2993431</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Broliden</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tolfvenstam</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Norbeck</surname>
            <given-names>O</given-names>
          </name>
          <article-title>Clinical aspects of parvovirus B19 infection</article-title>
          <source>J Intern Med</source>
          <year>2006</year>
          <volume>260</volume>
          <fpage>285</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2796.2006.01697.x</pub-id>
          <pub-id pub-id-type="pmid">16961667</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hatakka</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Piper</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tam</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Walkty</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Acute hepatitis as a manifestation of parvovirus B19 infection</article-title>
          <source>J Clin Microbiol</source>
          <year>2011</year>
          <volume>49</volume>
          <fpage>3422</fpage>
          <lpage>3424</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.00575-11</pub-id>
          <pub-id pub-id-type="pmid">21734024</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pinho</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Alves</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Vieira</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Moralez</surname>
            <given-names>MO</given-names>
          </name>
          <name>
            <surname>Fonseca</surname>
            <given-names>LE</given-names>
          </name>
          <name>
            <surname>Guz</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Wakamatsu</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Can&#xE7;ado</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Carrilho</surname>
            <given-names>FJ</given-names>
          </name>
          <name>
            <surname>da Silva</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Bernardini</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Durigon</surname>
            <given-names>EL</given-names>
          </name>
          <article-title>Detection of human parvovirus B19 in a patient with hepatitis. Detection of human parvovirus B19 in a patient with hepatitis</article-title>
          <source>Braz J Med Biol Res</source>
          <year>2001</year>
          <volume>34</volume>
          <fpage>1131</fpage>
          <lpage>1138</lpage>
          <pub-id pub-id-type="pmid">11514836</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pardi</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Romero</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Mertz</surname>
            <given-names>LE</given-names>
          </name>
          <name>
            <surname>Douglas</surname>
            <given-names>DD</given-names>
          </name>
          <article-title>Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: a report of two cases and a review of the literature</article-title>
          <source>Am J Gastroenterol</source>
          <year>1998</year>
          <volume>93</volume>
          <fpage>468</fpage>
          <lpage>470</lpage>
          <pub-id pub-id-type="pmid">9517662</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bousvaros</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sundel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Thorne</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>McIntosh</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Erdman</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Perez-Atayde</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Finkel</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Colin</surname>
            <given-names>AA</given-names>
          </name>
          <article-title>Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis</article-title>
          <source>Pediatr Pulmonol</source>
          <year>1998</year>
          <volume>26</volume>
          <fpage>365</fpage>
          <lpage>369</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1099-0496(199811)26:5&lt;365::AID-PPUL11&gt;3.0.CO;2-4</pub-id>
          <pub-id pub-id-type="pmid">9859908</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kishore</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Detection of parvovirus B19 in a case of erythema infectiosum with myositis</article-title>
          <source>Indian Pediatr</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>814</fpage>
          <lpage>817</lpage>
          <pub-id pub-id-type="pmid">17033121</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Watzinger</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Suda</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Preuner</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Baumgartinger</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ebner</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Baskova</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Niesters</surname>
            <given-names>HGM</given-names>
          </name>
          <name>
            <surname>Lawitschka</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lion</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients</article-title>
          <source>J Clin Microbiol</source>
          <year>2004</year>
          <volume>42</volume>
          <fpage>5189</fpage>
          <lpage>5198</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.42.11.5189-5198.2004</pub-id>
          <pub-id pub-id-type="pmid">15528714</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="other">
          <name>
            <surname>Bihari</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rastogi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rangegowda</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Chowdhury</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Saxena</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Garg</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sarin</surname>
            <given-names>SK</given-names>
          </name>
          <article-title>Parvovirus B19 associated acute hepatitis and hepatosplenomegaly</article-title>
          <source>Clin Res Hepatol Gastroenterol</source>
          <year>2013</year>
          <comment>10. [Epub ahead of print]</comment>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Etienne</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Melchior</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cornu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vandenbroucke</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Buts</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Burtonboy</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children</article-title>
          <source>Lancet</source>
          <year>1998</year>
          <volume>352</volume>
          <fpage>1739</fpage>
          <lpage>1741</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(98)06165-0</pub-id>
          <pub-id pub-id-type="pmid">9848349</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wong</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>KE</given-names>
          </name>
          <article-title>Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia</article-title>
          <source>J Infect Dis</source>
          <year>2003</year>
          <volume>187</volume>
          <fpage>1581</fpage>
          <lpage>1586</lpage>
          <pub-id pub-id-type="doi">10.1086/374781</pub-id>
          <pub-id pub-id-type="pmid">12721938</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Poole</surname>
            <given-names>BD</given-names>
          </name>
          <name>
            <surname>Karetnyi</surname>
            <given-names>YV</given-names>
          </name>
          <name>
            <surname>Naides</surname>
            <given-names>SJ</given-names>
          </name>
          <article-title>Parvovirus B19-induced apoptosis of hepatocytes</article-title>
          <source>J Virol</source>
          <year>2004</year>
          <volume>78</volume>
          <fpage>7775</fpage>
          <lpage>7783</lpage>
          <pub-id pub-id-type="doi">10.1128/JVI.78.14.7775-7783.2004</pub-id>
          <pub-id pub-id-type="pmid">15220451</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>D&#xED;az</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Collazos</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Hepatic dysfunction due to parvovirus B19 infection</article-title>
          <source>J Infect Chemother</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>63</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1007/s101560050052</pub-id>
          <pub-id pub-id-type="pmid">11810534</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Brown</surname>
            <given-names>KE</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>NS</given-names>
          </name>
          <article-title>Erythrocyte P antigen: cellular receptor for B19 parvovirus</article-title>
          <source>Science</source>
          <year>1993</year>
          <volume>262</volume>
          <fpage>114</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="doi">10.1126/science.8211117</pub-id>
          <pub-id pub-id-type="pmid">8211117</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rouger</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gane</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Salmon</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies</article-title>
          <source>Rev Fr Transfus Immunohematol</source>
          <year>1987</year>
          <volume>30</volume>
          <fpage>699</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="doi">10.1016/S0338-4535(87)80138-1</pub-id>
          <pub-id pub-id-type="pmid">3330858</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jordan</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Butchko</surname>
            <given-names>AR</given-names>
          </name>
          <article-title>Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody</article-title>
          <source>Placenta</source>
          <year>2002</year>
          <volume>23</volume>
          <issue>7</issue>
          <fpage>547</fpage>
          <lpage>553</lpage>
          <pub-id pub-id-type="doi">10.1053/plac.2002.0843</pub-id>
          <pub-id pub-id-type="pmid">12175970</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ho</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Juurlink</surname>
            <given-names>DN</given-names>
          </name>
          <article-title>Considerations when prescribing trimethoprim-sulfamethoxazole</article-title>
          <source>CMAJ</source>
          <year>2011</year>
          <volume>183</volume>
          <issue>16</issue>
          <fpage>1851</fpage>
          <lpage>1858</lpage>
          <comment>doi: 10.1503/cmaj.111152. Epub 2011 Oct 11</comment>
          <pub-id pub-id-type="doi">10.1503/cmaj.111152</pub-id>
          <pub-id pub-id-type="pmid">21989472</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Andrade</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Tulkens</surname>
            <given-names>PM</given-names>
          </name>
          <article-title>Hepatic safety of antibiotics used in primary care</article-title>
          <source>J Antimicrob Chemother</source>
          <year>2011</year>
          <volume>66</volume>
          <issue>7</issue>
          <fpage>1431</fpage>
          <lpage>1446</lpage>
          <comment>doi: 10.1093/jac/dkr159. Epub 2011 May 17</comment>
          <pub-id pub-id-type="doi">10.1093/jac/dkr159</pub-id>
          <pub-id pub-id-type="pmid">21586591</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kouklakis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Mpoumponaris</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zezos</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Moschos</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Koulaouzidis</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nakos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pehlivanidis</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Iosiphidis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Molyvas</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Nikolaidis</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole</article-title>
          <source>Ann Hepatol</source>
          <year>2007</year>
          <volume>6</volume>
          <issue>1</issue>
          <fpage>63</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">17297432</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="book">
          <name>
            <surname>Kucers</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Crowe</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Grayson</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Hoy</surname>
            <given-names>J</given-names>
          </name>
          <source>The Use of Antibiotics. A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs</source>
          <year>1997</year>
          <edition>5</edition>
          <publisher-name>Oxford, UK: Butterworth-Heinemann</publisher-name>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Nocton</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Tucker</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Schaller</surname>
            <given-names>JG</given-names>
          </name>
          <article-title>Human parvovirus B19-associated arthritis in children</article-title>
          <source>J Pediatr</source>
          <year>1993</year>
          <volume>122</volume>
          <fpage>186</fpage>
          <lpage>190</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-3476(06)80111-3</pub-id>
          <pub-id pub-id-type="pmid">8429430</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Oliver</surname>
            <given-names>ND</given-names>
          </name>
          <name>
            <surname>Millar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pendleton</surname>
            <given-names>A</given-names>
          </name>
          <article-title>A case report on parvovirus b19 associated myositis</article-title>
          <source>Case Rep Rheumatol</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>250537</fpage>
          <comment>doi: 10.1155/2012/250537. Epub 2012 Dec 10</comment>
          <pub-id pub-id-type="pmid">23304613</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Koliou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hadjiloizou</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ourani</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Demosthenous</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hadjidemetriou</surname>
            <given-names>A</given-names>
          </name>
          <article-title>A case of benign acute childhood myositis associated with influenza A (H1N1) virus infection</article-title>
          <source>Clin Microbiol Infect</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>193</fpage>
          <lpage>195</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1469-0691.2009.03064.x</pub-id>
          <pub-id pub-id-type="pmid">19832721</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Davis</surname>
            <given-names>LE</given-names>
          </name>
          <name>
            <surname>Kornfeld</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Experimental influenza B viral myositis</article-title>
          <source>J Neurol Sci</source>
          <year>2001</year>
          <volume>187</volume>
          <fpage>61</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-510X(01)00526-3</pub-id>
          <pub-id pub-id-type="pmid">11440746</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mackay</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Kornberg</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Shield</surname>
            <given-names>LK</given-names>
          </name>
          <name>
            <surname>Dennett</surname>
            <given-names>X</given-names>
          </name>
          <article-title>Benign acute childhood myositis: laboratory and clinical features</article-title>
          <source>Neurology</source>
          <year>1999</year>
          <volume>53</volume>
          <fpage>2127</fpage>
          <lpage>2131</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.53.9.2127</pub-id>
          <pub-id pub-id-type="pmid">10599793</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
